行情

CCXI

CCXI

ChemoCentryx
NASDAQ

实时行情|Nasdaq Last Sale

43.66
+2.73
+6.67%
盘后: 43.51 -0.15 -0.34% 16:58 01/17 EST
开盘
40.98
昨收
40.93
最高
43.89
最低
40.36
成交量
142.34万
成交额
--
52周最高
43.89
52周最低
6.16
市值
25.44亿
市盈率(TTM)
-47.2767
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CCXI 新闻

  • The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
  • Benzinga.1天前
  • Biotechs punch up talking points leading into big Union Square conference
  • American City Business Journals.01/10 23:00
  • Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 423% Share Price Gain?
  • Simply Wall St..01/10 10:01
  • ChemoCentryx Announces Credit Facility of Up to $100 Million with Hercules Capital
  • GlobeNewswire.01/09 13:30

更多

所属板块

制药
+0.13%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CCXI 简况

ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).
展开

Webull提供ChemoCentryx Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。